Our Story

Nine years in Quality at Amgen. Nine in Operational Excellence at Pfizer and Moderna. Now on your side of it.

Most pharma consulting arrives as a binder. A gap assessment, a maturity model, a roadmap, an invoice. Six months later the deviation backlog is the same size it was – and the people who live with the process day in and day out were never asked whether the solutions would address the root cause at all.

Biostrategenix was built to work the other way.

Ashish Airan spent nine years in Quality at Amgen and nine in Operational Excellence at Pfizer and Moderna, with further time at Rhodes Technologies and on consulting assignments — in quality systems, in operational excellence, on the floor during regulatory remediation, and in the rooms where a site decides whether to spend three million dollars on new equipment or find out why the old one keeps deviating. Across those roles he led programs delivering more than $65 million in verified value, designed the operational capability framework that a company deployed across its 37-site global network, and received Pfizer’s Global Annual Team Award for global site IMEx deployment and maturity.
He left because the traditional consulting model is structurally misaligned with how these problems actually get fixed. Large firms sell a senior name and staff the work with someone junior. They scope six-month engagements because six-month engagements are what their utilization model requires. And they separate quality from operations — so a manufacturer with a repeat-deviation problem ends up hiring one firm to fix the CAPA process and a second to fix the cycle time that causes the deviations.

Companies don’t need binders of theory. They need inspection readiness, quality investigations, CAPAs and change controls done right the first time — and the throughput problem underneath them fixed at the same time.

How We Are Built?

Biostrategenix is principal-led. Ashish personally leads every engagement, supported by a vetted bench of senior specialists brought in by name and by scope. We say this plainly because it is the entire point: the person who scopes your problem is the person standing in your plant. No handoff, no ramp-up, no junior consultant learning your process on your budget.

That structure has a limit, and we would rather name it than have you discover it. We take a small number of engagements at a time, and we scale by adding named senior specialists to a defined scope rather than bodies to a rate card. For a single workstream, the principal delivers it. For a multi-site remediation program, the principal leads it and every specialist is named, with a CV and a defined role, before work begins. What we will not do is staff a program with people learning your process on your budget. We are equally the firm for the problem a large firm won’t prioritize and your internal team can’t get to — the deviation backlog, the inspection eight weeks out, the site that has quietly missed its supply plan for three years, the two departments running conflicting SOPs on the same piece of equipment.

Why the Law degree is on this Page?

Ashish holds a Juris Doctor alongside a M.S. in Chemical Engineering and an ASQ Certified Six Sigma Black Belt.

In this work, that is not a curiosity.

A 483 response is a legal document written to a regulator who is building a record. Warning letter closeouts and consent decree commitments turn on precision about what you are committing to and what you are not. Very few people in this industry can draft that document and run the DMAIC project that makes the commitment true. That is why clients bring us in on the problems that sit at the seam between compliance and operations.